Consumer Health FemHealth Focus
Hims & Hers Enters APAC Market with Australia Launch Following Eucalyptus Acquisition
Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, announced it is now serving customers in Australia, marki...
September 03, 2026 | News
Cartherics Explores Tissue Factor-Targeting CAR-NK Therapies for Cancer and Endometriosis
Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immu...
September 03, 2026 | News
US FDA Approves BeOne’s TEVIMBRA-ZIIHERA Combination for First-Line HER2+ Gastroesophageal Cancer
TEVIMBRA plus ZIIHERA and chemotherapy is the first and only immunotherapy-based regimen to deliver more than two years of median OS in first-line HER2+ ...
August 27, 2026 | News
Metabolon Completes Gates Foundation-Funded Metabolomics Studies to Advance Women’s and Infant Health
nnovative sample collection methods developed through Gates Foundation-funded grant enable high-quality metabolomics biomarker discovery in populations fro...
August 27, 2026 | News
China Accepts Laekna’s NDA for Afuresertib in Advanced Breast Cancer
Laekna (2105.HK) announced that the New Drug Application (NDA) for LAE002 (afuresertib) has been accepted by the Center for Drug Evaluation (CDE) of China'...
August 13, 2026 | News
Haleon, A*STAR Launch Centrum Study on Metabolic Health in Midlife Asian Women
A new clinical study on the multivitamin and mineral supplement Centrum is designed to generate evidence on metabolic health in midlife Asian women - a g...
August 12, 2026 | News
Kelun-Biotech's TROP2 ADC sac-TMT Advances Toward First-Line TNBC Approval in China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application of its trophoblas...
August 03, 2026 | News
EU CHMP Backs Enhertu Plus Pertuzumab as First New First-Line HER2 Positive Metastatic Breast Cancer Treatment in Over a Decade
Recommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by ...
July 28, 2026 | News
Sofinnova-Backed Myricx Bio to Join Novartis in Up to $1.5 Billion ADC Deal
Sofinnova Partners co-led the seed investment in 2019 and has supported the company from founding through to exit The proposed acquisition combines th...
July 07, 2026 | News
Innovent and Lilly Expand China Oncology Partnership with Verzenios Commercialisation Agreement
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...
July 01, 2026 | News
AnHorn Medicines Secures FDA IND Clearance for First-in-Class CIPN Prevention Candidate
AnHorn Medicines announced that its lead neuroprotective candidate AH-008, being developed for the prevention of chemotherapy-induced peripheral neuro...
June 24, 2026 | News
Gesynta Pharma Reaches 50% Patient Enrollment in Phase II Endometriosis Trial of Vipoglanstat
Gesynta Pharma AB, a Swedish clinical stage pharmaceutical company focusing on chronic inflammatory diseases, today announced that 50% of the target of 190...
June 18, 2026 | News
Akeso Enrols First Patient in Phase Ib/II Trial of Next-Generation HER3 ADC AK138D1 for Advanced Breast Cancer
Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-202) evaluating its internally...
June 17, 2026 | News
Kazia Therapeutics Expands Paxalisib TNBC Trial Following Encouraging Early Safety Data
Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tolerability Data Kazia Therapeutics Limited (NASDAQ...
May 28, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
